Sane Vax Inc urges the NCI and FDA to establish a reliable HPV genotyping test for virology-based cervical cancer prevention in patient care.

In a letter addressed to the Director of the NCI, and the FDA commissioner, Sane Vax Inc, requested that these two federal agencies recommend a reliable human papillomavirus (HPV) genotyping test to support the national virology-based cervical cancer prevention programme for patient care. Sane Vax has opined that the NCI knows reliable HPV genotyping is based on using a PCR system with short target sequencing. Increased detection of HPV by Hologic Cervista in the data submitted to the FDA is a concern. In the letter, the company has pointed out that a senior NCI official had confirmed in a recently published comment, the NCIs agenda is to replace the traditional Papanicolaou (Pap) …